John L. Nitiss, Ph.D.
 |
John L. Nitiss Professor, Pharmacology Contact Information 1601 Parkview Avenue Room E521 Rockford, IL 61107 Office: (815)395-5583 Fax: (312) 996-0098 Email: jlnitiss@uic.edu |
Education
| DNA topoisomerases as targets for cancer chemotherapy (Related Publications) |
Mechanisms of DNA repair by non-homologous end-joining (Related Publications) |
| Using yeast to study the action of therapeutic agents (Related Publications) |
Roles of topoisomerases and other replication proteins in chromosme segregation and genome stability (Related Publications) |
Publications (2007-2012)
Chee GL, Bhattarai B, Daniel Gietz R, Alrushaid S, Nitiss, J.L., Hasinoff BB. Chemical reactivity and microbicidal action of bethoxazin. Bioorg Med Chem. 2012 Feb 15;20(4):1494-501. Epub 2012 Jan 5.
Bahmed, K., Seth, A., Nitiss, K.C., and Nitiss, J.L. End-processing during non-homologous end-joining: a role for exonuclease 1. Nucleic Acids Res. 39: 970-78, 2011.
Bahmed, K., Nitiss, K.C., and Nitiss, J.L. UnTTrapping the ends: a new player in overcoming protein linked DNA damage. Cell Res 20:122-123, 2010.
Bahmed, K., Nitiss, K.C., and Nitiss, J.L. Yeast Tdp1 regulates the fidelity of nonhomologous end joining. Proc Natl Acad Sci U S A, 107: 4057-62, 2010.
Nitiss, J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Rev Cancer. 9:338-50, 2009.
Nitiss, J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nature Rev Cancer 9:327-37, 2009.
Rogojina, A., Nitiss, J.L. Isolation and Characterization of mAMSA-hypersensitive Mutants CYTOTOXICITY OF Top2 COVALENT COMPLEXES CONTAINING DNA SINGLE STRAND BREAKS. J Biol Chem 283:29239-50, 2008
Morgan-Linnell, S.K., Hiasa, H., Zechiedrich E.L. and Nitiss J.L. Assessing sensitivity to anti-bacterial topoisomerase II inhibitors. Current Protocols in pharmacology. New York, NY: John Wiley and Sons, pp 3.13.1-3.13.26, 2008.
Stepanov, A., Nitiss, K.C., Neale G., and Nitiss, J.L. Enhancing drug accumulation in S. cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors. Mol Pharmacol. 74:423-31, 2008.
He, X., van Waardenburg, R.C., Babaoglu K., Price A.C., Nitiss K.C. , Nitiss J.L., Bjornsti M.A., White S.W. Mutation of a Conserved Active Site Residue Converts Tyrosyl-DNA Phosphodiesterase I into a DNA Topoisomerase I-dependent Poison. J Mol Biol 372:1070-81, 2007
Nitiss, J.L., and Heitman J. 2007. Yeast as tool in cancer research. Dordrecht: Springer DOI
Malik M., Nitiss K.C., Enriquez-Rios V., and Nitiss J.L. Roles of non-homologous end-joining pathways in surviving topoisomerase II mediated DNA damage., Mol. Cancer Therapeut., 5:1405-1414, 2006.
Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, Agama K, Nitiss JL, Redon C. Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol. 81:179-229, 2006.
Nitiss, KC., Malik M, He, X, White, SW, Nitiss, JL. Tyrosyl DNA phosphodiesterase 1 (Tdp1) participates in the repair of Top2 mediated DNA damage. Proc Natl Acad Sci U S A, 103:8953-57, 2006.
Gray, MD, Mann, M, Nitiss, J, Hendershot, LM. Activation of the UPR is necessary and sufficient for reducing topoisomerase II protein levels and decreasing sensitivity to topoisomerase targeted drugs, Mol. Pharmacol. 68:1699-1707, 2005.
Vaughn J, Huang S, Wessel I, Sorensen TK, Hsieh T, Jensen LH, Jensen PB, Sehested M, Nitiss JL. Stability of the topoisomerase II closed clamp conformation may influence DNA stimulated ATP hydrolysis. J Biol Chem. 280, 11920-11929, 2005.
.